Trigeminal neuralgia is a recurrent pain limited to one or more branches of the trigeminal nerve, characterized by a brief unilateral electric shock-like pain that occurs and is abruptly discontinued. The peak incidence is between 50 and 70 years of age, and 60% are women. Because of the complex mechanism of trigeminal neuralgia, involving central and peripheral nerve, vascular, immune and other multifaceted changes, and the intensity of clinical pain is very intense, effective pain control is a very important clinical topic. After nearly 10 years of exploration, a series of techniques for controlling trigeminal neuralgia have been summarized, and different analgesic schemes have been selected according to different disease duration, pain sites and systemic conditions of patients, so that 98% of outpatients can effectively control pain in the short term, the satisfaction rate in the medium term (more than half a year) is more than 85%, and the satisfaction rate in the long term (5 years) analgesia is more than 60%. The trigeminal nerve series analgesic techniques include the following: 1. Adequate and rotating oral medications. It includes the main drugs such as neurofilm stabilizer carbamazepine, phenytoin sodium, γ-aminobutyric acid, almotriptan, gabapentin, oxcarbazepine, etc., and auxiliary drugs such as central analgesics, neurotrophic drugs, immunomodulators, anti-inflammatory analgesics, etc. 2.Early trial of local anesthetic block analgesia. 3.Patients with long-term intermittent Ⅰ and Ⅱ branch attack pain use selective nerve destructive block: block the peripheral branches of trigeminal nerve with anhydrous ethanol, phenol glycerin or adriamycin. 4, Patients with long-term intermittent Ⅱ and Ⅲ branch attack pain should use transdermal puncture intracranial radiofrequency selective destructive block of the semilunar ganglion. The C-arm positioning combined with skin area stimulation potential-guided puncture for radiofrequency treatment of the semilunar ganglion, which we successfully studied, is economical and practical, with a high success rate of puncture, and can better control the extent of semilunar ganglion destruction and achieve the effect of branch selective blockade, which significantly improves the quality of treatment. Focus on differential diagnosis and active control of symptomatic trigeminal neuralgia: including herpes zoster virus infection, multiple sclerosis, tumor, vascular damage and other diseases.